Dianthus Therapeutics
€0
0
+€0+0% Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
People Also Follow
This list is based on the watchlists of people on Stock Events who follow 87E.MU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Show more...
CEO
Mr. Marino Garcia M.B.A.
Employees
78
Country
United States
ISIN
US2528281080
Listings
0 Comments
Share your thoughts
FAQ
What is Dianthus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Dianthus Therapeutics stocks are traded under the ticker 87E.MU.
How many employees does Dianthus Therapeutics have?▼
As of April 11, 2026, the company has 78 employees.
In which sector is Dianthus Therapeutics located?▼
Dianthus Therapeutics operates in the Health & Wellness sector.
When did Dianthus Therapeutics complete a stock split?▼
Dianthus Therapeutics has not had any recent stock splits.
Where is Dianthus Therapeutics headquartered?▼
Dianthus Therapeutics is headquartered in New York, United States.